NGNE logo

NEUROGENE INC

NGNENASDAQ
🏆 #2895 by market capUS Equity
$831.22▲ $12.88 (+1.55%)
Simulated price
🔔
Track NGNE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▲ 2375.3%
14d▲ 2373.9%
30d▲ 2184.8%
ytd▲ 3903.0%
1y▲ 4585.6%
🏦Market Cap
$570M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
80
Good

Trading Snapshot

Day Range
$823.95 – $841.65
52-Week Range
$15.93 – $43.66
Volume
$2.63B
Avg Volume
$3.10B
Shares Outstanding
19.7M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$139M
Last Q Revenue
$33M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-3.16
Dividend Yield
—
Dilution (1yr)
+4.3%

Why Investors Own NGNE

  • ✓High-growth profile — revenue up +38.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 48% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NGNE logo

NEUROGENE INC

NGNE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$103M▲ +24.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$78M▲ +9.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
15.5M▲ +4.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$94M▼ −$30M YoY
StockOtter · stockotter.space

About NEUROGENE INC

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$1,002.39
▲ +20.6% Upside
High Target$1,173.42
Low Target$938.55
Based on 29 analysts

Latest News & Updates

🚀
Barron’s·2h ago

NEUROGENE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift NGNE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

NEUROGENE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.